Our October patent highlights cover a diverse array of drug discovery IP disclosures. From piperidine-based USP19 inhibitors and small molecule GIPR antagonists for obesity to KCC2 potentiators for epilepsy, the month delivered a number of exciting IP developments. Other notable discoveries include MTA-cooperative PRMT5 inhibitors, direct-acting influenza antivirals against a novel target, Nrf2 activators for heart failure, and a slew of Polθ inhibitors for HR-deficient cancers.

Check out our searchable, annotated database featuring our curated selection of the most important drug discovery patents published in October 2024.

This article highlights key patents published in September 2024, covering a range of therapeutic targets and mechanisms. It includes Nurr1 and Nur77 modulators for oncology applications, STAT3 inhibitors and CRBN-based STAT3 degraders for modulating STAT3 signaling in cancer, and CDK2 molecular glue degraders for estrogen receptor-positive breast cancer resistant to CDK4/CDK6 inhibitors. Additionally, it features ERAP1 modulators for addressing autoimmune diseases, APOL1 inhibitors for APOL1-mediated kidney diseases, and novel NEK7 inhibitors targeting the NLRP3 inflammasome pathway.

Staying on top of the latest IP disclosures in drug discovery is no small feat, so we’ve made it easier for you! Our team sifted through thousands of recently published patents to compile a curated list of about 200 significant patent documents in the drug discovery space from September 2024. Each entry is accompanied by detailed annotations to help you quickly grasp the essentials.

This article highlights the key drug discovery patents published in August 2024, including AKR1C3-dependent KARS (not KRAS!) inhibitors for NRF2/KEAP1-mutated cancers and DHX9 helicase inhibitors of MSI-high tumors. It also covers the development of MK2 degraders for inflammatory diseases and small molecule IL-17A inhibitors that show promise in modulating inflammation. Additionally, we cover Roche’s take on Revolution Medicines’ macrocyclic pan-KRAS inhibitors, which show improved PK profiles, and novel non-hydroxamate LpxC inhibitors for treating Gram-negative bacterial infections.

We know keeping up with the latest developments in drug discovery can be a challenge, so we’ve simplified the process for you. We’ve reviewed thousands of newly published patent documents to bring you a curated list of over 200 key patents released in August 2024. Each entry comes with detailed commentary to help you navigate the content quickly and efficiently.

This article highlights a patent application from Monte Rosa Therapeutics that discloses the biological activity of compounds that act as VAV1 molecular glue degraders, providing a summary of key data for selected molecules disclosed in the patent application.

This article highlights a patent application from Constellation Pharmaceuticals that discloses the biological activity of compounds that act as TREX1 inhibitors, providing a summary of key data for selected molecules disclosed in the patent application.

This article highlights a patent application from AstraZeneca and Mitsubishi Tanabe, and Astellas Pharma that discloses the biological activity of compounds that act as NLRP3 inhibitors, providing a summary of key data for selected molecules disclosed in the patent application.

This article highlights a patent application from Arvinas that discloses the biological activity of compounds that act as tau-targeting heterobifunctional degraders, providing a summary of key data for selected molecules disclosed in the patent application.

This article highlights a patent application from Puhe BioPharma that discloses the biological activity of compounds that act as WRN helicase inhibitors, providing a summary of key data for selected molecules disclosed in the patent application.

To streamline your review of the patent literature, we've distilled thousands of new documents into a searchable table featuring over 200 selected patents focused on key areas in drug discovery, all published in July 2024. Each patent includes commentary for easier navigation and understanding.

To help you quickly scan the patent literature, we’ve distilled down thousands of new documents into a searchable table of over 200 selected patents focused on key areas in drug discovery, all published in June 2024. This resource is enriched with detailed highlights on selected molecules targeting high-interest areas such as synthetically lethal Polθ inhibitors, SARM1 inhibitors for neurodegenerative indications, and our best guess at the identity of Gilead’s small molecule GLP-1R agonist GS-4571

To help you quickly scan the patent literature, we’ve distilled down thousands of new documents into a searchable table of over 200 selected patents focused on key areas in drug discovery, all published in May 2024. This resource is enriched with detailed highlights on selected molecules targeting high-interest areas such as STING antagonists, WIZ degraders, RNA degraders, and macrocyclic amine-based OX2R modulators.

As part of our series of monthly patent roundup articles, which bring you highlights of the most relevant drug discovery IP disclosures, by member request we have collated recent selections into a single searchable table. This tool allows you to see longer-term industry trends in therapeutic areas and target selection to inspire ideas for your pipeline.

In April 2024, patent disclosures continued to highlight the swift progress in targeting key therapeutic areas. The Drug Hunter team has carefully compiled a searchable database containing over 200 patents relevant to drug discovery. This resource is enhanced with detailed annotations and highlights some of the most promising molecules and targets, such as GPR84 antagonists, brain-penetrant TYK2 inhibitors, and tricyclic urea JAK2 V617F inhibitors, among others. This compilation serves as a valuable tool for drug hunters to stay abreast of the latest trends in drug discovery.

In March 2024, the landscape of patent disclosures continued to reflect the rapid pace of advances against key therapeutic targets. The Drug Hunter team has curated a searchable database encompassing over 200 patents pertinent to the field of drug discovery. This resource is further enriched with insightful spotlight on some of the most promising molecules and targets, including OX2R agonists, TEAD covalent inhibitors, NaV1.8 inhibitors, and selective PI3Kγ inhibitors, among others. This round-up provides a valuable tool for drug hunters to navigate the most recent trends in drug discovery.

February 2024 saw numerous notable patent disclosures aimed at a variety of therapeutic targets across different disease areas. The Drug Hunter team has compiled a searchable table that includes more than 200 patents of relevance to the drug discovery industry. Accompanying the table are detailed notes, as well as standout features from some of our top picks, including MTA-cooperative PRMT5 inhibitors, heterobifunctional TYK2 degraders, strategies for engaging and reactivating mutant p53, and more.

From WRN helicase to KRAS G12V, there were numerous hot targets of interest with patent applications published in January 2024. Here, we curated a searchable table comprising key information for more than 200 patents from January 2024 of potential interest to drug hunters, along with highlights from some of our favorites, including several degraders and molecules targeting Nrf2, KRAS G12V, MAGL, WRN, among others.

The Drug Hunter team is piloting a new series highlighting notable disclosures in the patent literature to provide our readers a timely and scientifically flavorful synopsis of therapeutic targets being actively pursued, emerging industry breakthroughs, and fascinating chemical matter. Here we highlight 12 patents published in December 2023 that piqued our interest, and compiled a searchable table comprising key information from more than 180 additional patents of potential interest to drug hunters. If you have any suggestions on how to make this more useful, please let us know!

This article highlights million-dollar molecules that were recently in the news with related patent applications that give clues to their structures and properties. This edition includes Maze’s glycogen synthase 1 (GYS1) inhibitors that were recently licensed to Sanofi, allosteric androgen receptor (AR) modulators that may be of interest to targeted protein degradation researchers, brain-penetrant HER2 and ROCK2 inhibitors, and MDM2 degraders.